david_mott_adaptimmune

Adaptimmune board changes amid funding boost

pharmafile | September 29, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adaptimmune, Ali Behbahani, Elliott Sigal, Peter Thompson, david mott 

Oxford-based biotech firm Adaptimmune has secured some significant financial support whilst also making changes to its board.

David Mott (pictured), NEA general partner and head of healthcare; Dr Ali Behbahani, a partner in NEA’s healthcare team, and Dr Peter Thompson, a private equity partner at OrbiMed, have been appointed as non-executive directors.

They will serve alongside the existing Adaptimmune chairman Dr Jonathan Knowles, and chief executive James Noble. The board is to be further strengthened by Dr Elliott Sigal, former chief scientific officer and executive VP of Bristol Myers-Squibb, who joins as an independent industry representative.

Advertisement

The shake-up sits beside the completion of a $104 million financing round for the firm from several investors. Adaptimmune plans to use the proceeds from the funding to advance the company’s internal programmes into the clinic in multiple cancer indications.

“We are very pleased to be leading this round in Adaptimmune against a backdrop of increasing global interest in the immuno-oncology field”, says Mott. “We look forward to working closely with the company to rapidly progress the development of its innovative research pipeline in TCR T-cell therapy, which offers an opportunity to bring potentially breakthrough cancer treatments to patients.”

Related Content

Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour

Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given …

adaptimmune_lab_scientists_growing_research_cells_jpg-web

Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial

Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a …

Adaptimmune

GSK and Adaptimmune expand R&D collaboration

Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run …

The Gateway to Local Adoption Series

Latest content